Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.34 |
| ▸ | MLYCD | O95822 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822454 | 0.86 | KCNN4 (0.33) | KCNN4KCNA3RORCEGLN1 | |
| SCHEMBL2262046 | 0.86 | MLYCD (0.35) | KCNN4KCNA3NR1H3NR1H2MLYCD | |
| SCHEMBL3434620 | 0.75 | LMNA (0.35) | KCNN4KCNA3KDM4ELMNAPOLB | |
| SCHEMBL2259617 | 0.75 | PLAU (0.37) | HSD11B1 | |
| SCHEMBL2257964 | 0.74 | NR1H2 (0.55) | NR1H3NR1H2MLYCDHSD11B1 | |
| SCHEMBL1829650 | 0.72 | KCNN4 (0.42) | KCNN4KCNA3 | |
| SCHEMBL1816637 | 0.71 | — | — | |
| SCHEMBL2262780 | 0.71 | — | — | |
| SCHEMBL2258952 | 0.71 | MEN1 (0.31) | — | |
| SCHEMBL2497436 | 0.70 | EPHX2 (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | KCNB1, KCNA5, KCNA7 | KCNN4 430/4885KCNA3 6/4885NR1H3 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.